Press Release

PhRMA Statement on Appointment of White House Health Czar

PhRMA April 24, 2013

Washington, D.C. (March 2, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today regarding Nancy-Ann DeParle’s selection to head the White House Office of Health Reform:

“Nancy-Ann DeParle certainly brings a lot to the table with her breadth of experience in healthcare issues. Her appointment today complements the nomination of Governor Kathleen Sebelius as Secretary of the Department of Health and Human Services.

“In addition to her public service as head of the Health Care Financing Administration – now the Centers for Medicare and Medicaid Services – and her time at the Office of Management and Budget, she has played meaningful roles in the private, academic and non-profit sectors. With such an impressive background, DeParle will undoubtedly play an important leadership role in helping to drive comprehensive healthcare reform through a bipartisan, collaborative process.

“As President Obama outlined in his recent address to Congress, comprehensive health reform must remain a priority so that all Americans can access high-quality and affordable healthcare coverage. PhRMA couldn’t agree more. The President’s commitment to this issue is evident in his decision to create a new health reform office at the White House and also with the appointment of such a highly qualified leader to head this office.

“Last year, PhRMA unveiled its own healthcare reform platform. Our plan stresses the need to build on the existing employer-based system and expanding coverage through a public-private approach – with a focus on private health insurance expansions and leveraging such public health insurance programs as the recently reauthorized State Children’s Health Insurance Program.

“America’s pharmaceutical research and biotechnology companies remain committed to working with the Administration and members of Congress to help make comprehensive health reform a reality as well as helping maintain an innovative environment that can lead to future cures for diseases such as cancer.”


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the danger of imported drugs, visit: